Vascular Pharmaceuticals, Inc. is focused on the development and commercialization of novel
therapeutics targeting the treatment of diabetes associated complications.
Founded in 2005 by Dr. David R. Clemmons,
Chief of the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill,
the company has three active research programs focused on diabetic atherosclerosis, retinopathy and obesity.
Vascular Pharma's lead compound is a therapeutic antibody currently undergoing humanization that offers a novel
approach to antagonize a signaling pathway implicated in atherosclerosis development in diabetics.
Vascular Pharma's Research
Our lead product candidate works in the insulin-like growth factor-I (IGF-1) signaling pathway.
It binds to a unique site on the αVβ3 receptor and inhibits IGF-1 mediated smooth muscle cell proliferation stimulated
by hyperglycemia (more...)
The Burden of Diabetes
The Centers for Disease Control (CDC) estimates there are over 24 million diabetics in the U.S.,
while another 57 million adults have pre-diabetes.
The health complications associated with the disease are significant and include enhanced cardiovascular risk,
renal impairment, blindness, and peripheral nervous system damage that can lead to amputations.
The annual direct healthcare cost of diabetes is estimated at $116 billion,
and diabetics incur approximately 2.3 times the healthcare expenditures as non-diabetics.
Recent News: Equity Financing Completed
On September 11, 2012, VPI announced the completion of $16M in equity financing and an agreement with Janssen Biotech.
(Read the full Press Release...)